Heart disease remains the leading cause of death worldwide. The proliferation of heart issues — paired with lifestyle factors that complicate patient recruitment and study design — reflect an urgent need for expert-led clinical trials. Moreover, intersections among heart health and metabolic research offer promising opportunities to confront diseases affecting a growing, aging population, and … Read more
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research. As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, mentions … Read more
Velocity recently asked some key employees to come together and discuss a wide array of issues impacting diversity, equity, and inclusion (DEI) in clinical trials. Velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical trial science and … Read more
Évelyne Newton and Sylwia Kołodziej recently made the journey overseas to join our CARE Council summit in Durham, NC. Along with dozens of our physicians and operational, commercial, and recruitment leaders, they helped define a strategy to extend the reach of new and existing CARE Councils. As they mention in this video, by enhancing the … Read more
Velocity has won the 2024 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Company at The World Vaccine Congress in Washington, DC. The recognition is based on performance metrics, diversity of vaccine trial capabilities, and key initiatives to support vaccine research. Highlights of our groundbreaking initiatives and achievements throughout the past year include: The … Read more
Last month, Nick Spittal, Velocity’s chief operating officer announced the company’s latest partnership with HealthMatch and results from an unprecedented patient recruitment pilot at the SCOPE conference in Orland, Florida. He was joined by HealthMatch CEO, Manuri Gunawardena, on stage for a joint presentation, as Clinical Trials Report journalist Michael Causey reports: Velocity announced its … Read more
Velocity recently convened more than 40 leaders from around the world for a summit on Councils to Accelerate Research Excellence (CARE). Each CARE Council comprises key opinion leaders, Principal Investigators, and operational experts from Velocity sites worldwide. The summit focused on Velocity’s Diabetes + Obesity, MASH, Vaccine, Cardiology, and Women’s Health CARE Councils, along with … Read more
It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA, Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council, discusses their importance to patients yesterday, today, and tomorrow. Dr. Cromwell is board-certified in Family Medicine and Clinical Lipidology with over 20 years of clinical research experience. As he … Read more
Despite a boom in tech funding and monumental advancements in AI/ML and in silico models, tech advancements have not yet translated into marked efficiency improvements at clinical research sites. Most clinical trials still fail to meet enrollment timelines, with most delays occurring at the site level. To gain efficiency, technology must enhance clinical trials at … Read more
“[Patient centricity] is about taking those patient insights and their voice and translating them into actions. And that was really the impetus for what we saw in Velocity’s submission.” – Pat Roselle, Global Head of Patient Stakeholder Engagement at Sanofi. Thank you to Pat and Jimmy Bechtel for joining Nick Spittal to discuss the initiatives … Read more